Phio Pharmaceuticals Corp
PHIO1.050USD
+0.020+1.94%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
6.07MMarket Cap
LossP/E TTM
More Details of Phio Pharmaceuticals Corp Company
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Phio Pharmaceuticals Corp Info
Ticker SymbolPHIO
Company namePhio Pharmaceuticals Corp
IPO dateMay 10, 2012
CEOBitterman (Robert J)
Number of employees5
Security typeOrdinary Share
Fiscal year-endMay 10
Address411 Swedeland Road
CityKING OF PRUSSIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19406
Phone15087673861
Websitehttps://phiopharma.com/
Ticker SymbolPHIO
IPO dateMay 10, 2012
CEOBitterman (Robert J)
Company Executives of Phio Pharmaceuticals Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Robert J. Bitterman
Mr. Robert J. Bitterman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
283.04K
+3.66%
Dr. Curtis A. Lockshin, Ph.D.
Dr. Curtis A. Lockshin, Ph.D.
Independent Director
Independent Director
16.56K
+4550.56%
Mr. David H. Deming
Mr. David H. Deming
Independent Director
Independent Director
14.00K
--
Ms. Patricia A. (Pat) Bradford
Ms. Patricia A. (Pat) Bradford
Independent Director
Independent Director
--
--
Ms. Lisa Carson
Ms. Lisa Carson
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
--
--
Dr. Jonathan E. Freeman, Ph.D.
Dr. Jonathan E. Freeman, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert J. Bitterman
Mr. Robert J. Bitterman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
283.04K
+3.66%
Dr. Curtis A. Lockshin, Ph.D.
Dr. Curtis A. Lockshin, Ph.D.
Independent Director
Independent Director
16.56K
+4550.56%
Mr. David H. Deming
Mr. David H. Deming
Independent Director
Independent Director
14.00K
--
Ms. Patricia A. (Pat) Bradford
Ms. Patricia A. (Pat) Bradford
Independent Director
Independent Director
--
--
Ms. Lisa Carson
Ms. Lisa Carson
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
--
--
Dr. Jonathan E. Freeman, Ph.D.
Dr. Jonathan E. Freeman, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Orca Capital GmbH
5.00%
Bitterman (Robert J)
2.63%
The Vanguard Group, Inc.
0.81%
Geode Capital Management, L.L.C.
0.54%
Nomura Investment Management Business Trust
0.46%
Other
90.55%
Shareholders
Shareholders
Proportion
Orca Capital GmbH
5.00%
Bitterman (Robert J)
2.63%
The Vanguard Group, Inc.
0.81%
Geode Capital Management, L.L.C.
0.54%
Nomura Investment Management Business Trust
0.46%
Other
90.55%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.67%
Individual Investor
4.14%
Investment Advisor/Hedge Fund
0.54%
Research Firm
0.03%
Other
88.62%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
32
624.70K
10.91%
-230.73K
2025Q2
36
845.32K
17.62%
+451.08K
2025Q1
36
775.62K
16.17%
+505.98K
2024Q4
32
296.95K
9.15%
+222.42K
2024Q3
32
80.42K
6.72%
+23.30K
2024Q2
31
23.09K
4.32%
-37.39K
2024Q1
33
20.92K
3.89%
-41.19K
2023Q4
35
59.17K
22.55%
+23.31K
2023Q3
40
35.14K
14.50%
-1.09K
2023Q2
42
33.69K
17.19%
+22.39K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Orca Capital GmbH
280.64K
4.9%
-234.32K
-45.50%
Aug 04, 2025
Bitterman (Robert J)
273.04K
4.77%
+245.89K
+905.70%
Sep 11, 2025
The Vanguard Group, Inc.
48.66K
0.85%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
57.69K
1.01%
+16.11K
+38.73%
Jun 30, 2025
Nomura Investment Management Business Trust
50.00K
0.87%
--
--
Jul 31, 2025
Carson (Lisa Cabott)
47.00K
0.82%
+47.00K
--
Sep 11, 2025
Ferrara (Robert L)
38.77K
0.68%
+23.10K
+147.45%
Sep 11, 2025
Cetera Investment Advisers LLC
32.50K
0.57%
-6.00K
-15.58%
Jun 30, 2025
Bradford Patricia A
19.15K
0.33%
+18.80K
+5340.91%
Sep 11, 2025
Lockshin (Curtis A)
16.56K
0.29%
+16.20K
+4550.56%
Sep 11, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 02, 2024
Merger
9→1
Jul 02, 2024
Merger
9→1
Jul 02, 2024
Merger
9→1
Jul 02, 2024
Merger
9→1
Jan 25, 2023
Merger
12→1
Jan 25, 2023
Merger
12→1
Date
Type
Ratio
Jul 02, 2024
Merger
9→1
Jul 02, 2024
Merger
9→1
Jul 02, 2024
Merger
9→1
Jul 02, 2024
Merger
9→1
Jan 25, 2023
Merger
12→1
Jan 25, 2023
Merger
12→1
Jan 25, 2023
Merger
12→1
Jan 25, 2023
Merger
12→1
FAQs
Who are the top five shareholders of Phio Pharmaceuticals Corp?
The top five shareholders of Phio Pharmaceuticals Corp are:
Orca Capital GmbH holds 280.64K shares, accounting for 4.90% of the total shares.
Bitterman (Robert J) holds 273.04K shares, accounting for 4.77% of the total shares.
The Vanguard Group, Inc. holds 48.66K shares, accounting for 0.85% of the total shares.
Geode Capital Management, L.L.C. holds 57.69K shares, accounting for 1.01% of the total shares.
Nomura Investment Management Business Trust holds 50.00K shares, accounting for 0.87% of the total shares.
Orca Capital GmbH holds 280.64K shares, accounting for 4.90% of the total shares.
Bitterman (Robert J) holds 273.04K shares, accounting for 4.77% of the total shares.
The Vanguard Group, Inc. holds 48.66K shares, accounting for 0.85% of the total shares.
Geode Capital Management, L.L.C. holds 57.69K shares, accounting for 1.01% of the total shares.
Nomura Investment Management Business Trust holds 50.00K shares, accounting for 0.87% of the total shares.
What are the top three shareholder types of Phio Pharmaceuticals Corp?
The top three shareholder types of Phio Pharmaceuticals Corp are:
Orca Capital GmbH
Bitterman (Robert J)
The Vanguard Group, Inc.
Orca Capital GmbH
Bitterman (Robert J)
The Vanguard Group, Inc.
How many institutions hold shares of Phio Pharmaceuticals Corp (PHIO)?
As of 2025Q3, 32 institutions hold shares of Phio Pharmaceuticals Corp, with a combined market value of approximately 624.70K, accounting for 10.91% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -6.71%.
What is the biggest source of revenue for Phio Pharmaceuticals Corp?
In --, the -- business generated the highest revenue for Phio Pharmaceuticals Corp, amounting to -- and accounting for --% of total revenue.
